- Home
- LEXX vs ENLV Comparison
LEXX vs ENLV Comparison
Compare LEXX & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEXX
- ENLV
- Stock Information
- Founded
- LEXX 2004
- ENLV 2005
- Country
- LEXX Canada
- ENLV Israel
- Employees
- LEXX N/A
- ENLV N/A
- Industry
- LEXX Biotechnology: Pharmaceutical Preparations
- ENLV Biotechnology: Pharmaceutical Preparations
- Sector
- LEXX Health Care
- ENLV Health Care
- Exchange
- LEXX Nasdaq
- ENLV Nasdaq
- Market Cap
- LEXX 22.7M
- ENLV 26.6M
- IPO Year
- LEXX N/A
- ENLV 1995
- Fundamental
- Price
- LEXX $1.08
- ENLV $1.00
- Analyst Decision
- LEXX Strong Buy
- ENLV Strong Buy
- Analyst Count
- LEXX 1
- ENLV 2
- Target Price
- LEXX $4.00
- ENLV $10.00
- AVG Volume (30 Days)
- LEXX 283.7K
- ENLV 155.0K
- Earning Date
- LEXX 11-25-2025
- ENLV 11-28-2025
- Dividend Yield
- LEXX N/A
- ENLV N/A
- EPS Growth
- LEXX N/A
- ENLV N/A
- EPS
- LEXX N/A
- ENLV N/A
- Revenue
- LEXX $615,923.00
- ENLV N/A
- Revenue This Year
- LEXX $46.98
- ENLV N/A
- Revenue Next Year
- LEXX $17.26
- ENLV N/A
- P/E Ratio
- LEXX N/A
- ENLV N/A
- Revenue Growth
- LEXX 49.85
- ENLV N/A
- 52 Week Low
- LEXX $0.77
- ENLV $0.81
- 52 Week High
- LEXX $2.85
- ENLV $2.10
- Technical
- Relative Strength Index (RSI)
- LEXX 58.89
- ENLV 36.86
- Support Level
- LEXX $0.99
- ENLV $1.03
- Resistance Level
- LEXX $1.21
- ENLV $1.07
- Average True Range (ATR)
- LEXX 0.08
- ENLV 0.04
- MACD
- LEXX 0.02
- ENLV -0.01
- Stochastic Oscillator
- LEXX 64.58
- ENLV 11.11
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.